CeNeRx completes $4.85 million financing round
CeNeRx BioPharma has completed a $4.85 million financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds all participated in the financing. CeNeRx plans to use the proceeds to complete its ongoing phase II trial of the improved formulation of its novel antidepressant TriRima as monotherapy in treatment resistant depression, as well as to support advancement of its pipeline for a variety of CNS disorders.
"Our phase II trial of TriRima in treatment resistant depression is proceeding very well and these funds will primarily be used to help complete the study,” said Barry Brand, chief executive officer of CeNeRx.